Visceral Leishmaniasis (VL) is the most fatal form of disease leishmaniasis. To date, there
are no effective prophylactic measures and therapeutics available against VL. Recently, new …

Visceral leishmaniasis (VL), commonly known as kala-azar, is caused by Leishmania
donovani and Leishmania infantum (Leishmania chagasi in the Americas). These …

Diseases caused by Leishmania present a worldwide problem, and current therapeutic
approaches are unable to achieve a sterile cure. Leishmania is able to persist in host cells …

Leishmaniasis, a neglected parasitic disease caused by a unicellular protozoan of the
genus Leishmania, is transmitted through the bite of a female sandfly. The disease remains …

Visceral leishmaniasis is a chronic parasitic disease associated with severe immune
dysfunction. Treatment options are limited to relatively toxic drugs, and there is no vaccine …

Canine leishmaniosis (CanL) is caused by the parasite Leishmania infantum and is a
systemic disease, which can present with variable clinical signs, and clinicopathological …

Leishmaniasis is a zoonotic and vector-borne infectious disease that is caused by the genus
Leishmania belonging to the trypanosomatid family. The protozoan parasite has a digenetic …

Visceral leishmaniasis (VL) is a chronic and often fatal disease caused by protozoans of the
genus Leishmania that affects millions of people worldwide. Patients with symptomatic VL …

The outcomes of Leishmania infection are determined by host immune and nutrition status,
parasite species, and co-infection with other pathogens. While subclinical infection and self …

T cell defect is a common feature in lepromatous or borderline lepromatous leprosy (LL/BL)
patients in contrast to tuberculoid or borderline tuberculoid type (TT/BT) patients …